key: cord-1045829-ku4cip50
authors: Frantz, Phanramphoei N.; Barinov, Aleksandr; Ruffié, Claude; Combredet, Chantal; Najburg, Valérie; Teeravechyan, Samaporn; Jongkaewwattana, Anan; Prot, Matthieu; Conquet, Laurine; Montagutelli, Xavier; Fernandes, Priyanka; Strick-Marchand, Hélène; Di Santo, James; Simon-Lorière, Etienne; Gerke, Christiane; Tangy, Frédéric
title: A measles-vectored COVID-19 vaccine induces long-term immunity and protection from SARS-CoV-2 challenge in mice
date: 2021-02-17
journal: bioRxiv
DOI: 10.1101/2021.02.17.431630
sha: c136c14b889e4e098d85f07db2ba913c46c09366
doc_id: 1045829
cord_uid: ku4cip50

In light of the expanding SARS-CoV-2 pandemic, developing efficient vaccines that can provide sufficient coverage for the world population is a global health priority. The measles virus (MV)-vectored vaccine is an attractive candidate given the measles vaccine’s extensive safety history, well-established manufacturing process, and induction of strong, long-lasting immunity. We developed an MV-based SARS-CoV-2 vaccine using either the full-length spike (S) or S2 subunit as the antigen. While the S2 antigen failed to induce neutralizing antibodies, the prefusion-stabilized, full-length S (MV-ATU2-SF-2P-dER) construct proved to be an attractive vaccine candidate, eliciting strong Th1-dominant T-cell and neutralizing antibody responses against the S antigen while minimizing reactivity to the vector itself. Neutralizing antibody titers remained high three months after homologous prime-boost immunization, and infectious virus was undetectable in all animals after challenge with a mouse-adapted SARS-CoV-2 virus.

of the S protein into S1 and S2 subunits by host proteases 6 is essential for viral infection. The S1 64 subunit contains the receptor-binding-domain (RBD), which enables the virus to bind to its entry 65 receptor, the angiotensin-converting enzyme 2 (ACE2) 4, 7 . After docking with the receptor, the S1 66 subunit is released and the S2 subunit reveals its fusion peptide to mediate membrane fusion and 67 viral entry 8 . 68

The coronavirus S protein contains the major epitopes targeted by neutralizing antibodies 69 and is thus considered as a main antigen for developing vaccines against human coronaviruses 70 8, 9, 10, 11, 12 . Antibodies targeting the RBD may neutralize virus by blocking viral binding to receptors 71 on host cells and preventing entry. Additionally, it has been observed that synthetic peptides 72 mimicking and antibodies targeting the second heptad region (HR2) in the S2 subunit of SARS-73

CoV have strong neutralizing activity 13, 14, 15, 16, 17 , likely by preventing the conformational changes 74 in preclinical and clinical trials 18 . An rMV-based vaccine against chikungunya virus was 78 demonstrated to be well-tolerated and immunogenic in phase I and II clinical trials, eliciting 90% 79 seroconversion after a single immunization and 100% after boost despite the presence of 80 preexisting measles immunity in volunteers 19, 20 . Other MV-based candidates currently in clinical 81 development include vaccines against Zika and Lassa viruses 21, 22 . We also previously showed 82 that rMV expressing the unmodified SARS-CoV-1 S protein induced a Th1-oriented response with 83 high titers of neutralizing antibodies that protected immunized mice from infectious intranasal 84 challenge by SARS-CoV-1 9 . The MV-MERS-CoV vaccine has also yielded promising preclinical 85 results 23 . Given the excellent safety and efficacy profiles of these vaccine candidates, an MV-86 based vaccine targeting the S protein of SARS-CoV-2 has great potential to be both safe and 87 effective. 88 (S. Fig.5 ). In contrast, its 2P counterpart was stably and efficiently expressed up to passage 10. 162

The sequence of MV-ATU2-SF-dER genome was also confirmed by Next-Generation 163 Sequencing (NGS) (S. Fig.6) , with no mutations detected in the antigen. Therefore, we discarded 164 the vaccine candidates expressing native S and selected those expressing the prefusion-165 stabilized SF-2P and S2-2P constructs for further immunogenicity studies. 166 167

We investigated the immunogenicity of selected rMV vaccine candidates in IFNAR -/mice 169 susceptible to MV infection 34 . Animals were immunized by one or two intraperitoneal 170 administrations of the rMV candidates at 1x10 5 TCID50 on days 0 and 30 (Fig. 3a) . Empty MV 171

Schwarz was used for control vaccination. Mice sera were collected 4 weeks after the prime and 172 12 days after the boost. The presence of S-and MV-specific IgG antibodies was assessed by 173 indirect ELISA using SARS-CoV-2 S recombinant protein and native MV antigens, respectively. 174

All animals raised high MV-specific IgG antibodies after prime at comparable titers in all 175 groups (~10 4 -10 5 IgG titer), indicating efficient vaccine take in all the animals (Fig. 3b) . Boost 176 immunization increased MV-specific antibody titers in all groups, indicating that all animals 177 received a successful prime-boost vaccination. Specific IgG antibodies to SARS-CoV-2 S were 178 detected in 100% of immunized mice. Interestingly, rMVs expressing SF-2P-dER or S2-2P-dER 179 antigens from ATU2 elicited higher levels of anti-S antibodies than the ATU3 vectors, particularly 180 after boosting (Fig. 3c) . Pre-immune sera and sera from control animals that received empty MV 181 remained negative for anti-S antibodies (data not shown). 182

We next assessed the presence of SARS-CoV-2 neutralizing antibodies (NAbs) using 183 plaque reduction neutralization tests (PRNT) with SARS-CoV-2 virus infection of Vero E6 184 monolayers. After the prime, SARS-CoV-2 NAbs were found in all mice immunized with SF-2P-185 dER expressed from ATU2 but only one mouse immunized with the ATU3 construct (Fig. 3d) . 186

After the second immunization, NAb titers increased in both groups, with the ATU2 group 187 exhibiting ten-fold higher NAb titers compared to the ATU3 group. No NAbs were detected in 188 animals immunized with the S2 candidates despite the high levels of anti-S antibodies (Fig. 3c) . 189

As IgG isotype switching can serve as indirect indicators of Th1 and Th2 responses 35 , we 190 determined S-specific IgG1 and IgG2a isotype titers in the sera of immunized mice (Fig. 3f, g) . 191

Similar to our previous results 9 , rMV candidates elicited significantly higher IgG2a antibody titers 192 than IgG1, reflecting a predominant Th1-type immune response (Fig. 3f, g) . Since activated T 193 cells play important roles in shaping Th1 and Th2 cytokine production, we analyzed S-specific T-194 cell responses in MV-immunized mice in more detail. 195 196

Cell-mediated immune responses elicited by immunization were first investigated using an IFN-γ 198 ELISPOT assay. Groups of IFNAR -/mice were sacrificed one week after prime immunization (Fig.  199 4a). To evaluate S-specific responses, splenocytes were stimulated ex vivo with a pool of 200 synthetic peptides covering the predicted CD8 + and CD4 + T-cell epitopes of the SARS-CoV-2 S 201 protein, matching the MHC-I H-2K b /H-2D b and MHC-II I-A b haplotype of 129sv IFNAR -/mice 202 (S. Table 1 ). Splenocytes were also stimulated with an empty MV virus to detect MV vector-specific 203

High levels of T-cell responses to SARS-CoV-2 S and MV were elicited early after prime 205 vaccination (Fig. 4) . Splenocytes from mice vaccinated with MV-ATU2-SF-2P-dER yielded 206 remarkably high IFN-γ secretion levels after stimulation with an MHC class I-restricted S peptide 207 pool, yielding around 2,500 spot forming cells (SFC) per 10 6 splenocytes. Lower IFN-γ responses 208

were observed upon stimulation with MHC class II-restricted S peptides, at approximately 400 209 SFC/10 6 splenocytes (Fig. 4b, c) . Splenocytes of these mice also exhibited relatively low vector-210 specific IFN-γ responses (~990 SFC/10 6 splenocytes), indicating a well-balanced S-to-MV vector 211 response ratio (Fig. 4d) . The ATU3 counterpart of the same vaccine tended to generate more 212 vector-specific IFN-γ secreting cells (~1,320 SFC/10 6 splenocytes), while at the same time being 213 less efficient in producing S-specific IFN-γ secreting cells after stimulation with MHC class II-214 restricted S peptides (~130 SFC/10 6 splenocytes). While IFN-γ responses after stimulation with 215 MHC class I-restricted S peptides were not significantly different from those of its ATU2 216 counterpart (~1,980 SFC/10 6 splenocytes), the S-to-MV vector response ratio was significantly 217 higher for MV-ATU2-SF-2P-dER (Fig. 4b) . 218

In contrast, S-specific IFN-γ responses elicited by S2-only constructs were low after 219 stimulation with either of the S peptide pools (Fig. 4c, d) . S-to-MV vector response ratios also 220 remained very low in these animals, suggesting that immunization with the S2 protein subunit 221 alone might be not sufficient to induce strong protective cellular immune responses (Fig. 4e, f) . 222

MV-ATU3-S2-2P-dER and empty MV were unable to induce S-specific IFN-γ responses. 223

We next studied S-specific CD4 + and CD8 + T cells by flow cytometric analysis after 224 intracellular cytokine staining (ICS). S-specific IFN-γ + and TNF-α + responses were observed in for 225 CD8 + T cells, while CD4 + T cells responded poorly to S peptide pool stimulation (Fig. 5a, b) . 226

Similar to the ELISPOT results, SF-2P-dER expressed from ATU2 or ATU3 induced remarkably 227 high and comparable percentages of S-specific IFN-γ + and TNF-α + CD8 + T cells, while the S2 228 protein expressed from ATU2 was ten times less immunogenic. MV-ATU3-S2-2P-dER and empty 229 MV were unable to induce S-specific IFN-γ-or TNF-α-producing T-cells. IL-5-secreting cells 230

(indicative of a Th2-biased response) were not detected in any of the immunization groups. An 231 additional detailed analysis of T cell responses in mice immunized with MV-ATU2-SF-2P-dER 232 confirmed the strong stimulation of CD8 compartment with high levels of S-specific IFN-γ + and 233 TNF-α + producing CD8 + T cells, as well as double positive IFN-γ + / TNF-α + producing CD8 + T 234 cells. No IL-5 or IL-13 was detected in CD4 + or CD8 + T cells, as well as in CD4 + / CD44 + / CD62L -235 memory T cells, confirming that S-specific memory T cells are also Th1-oriented (S. Fig. 7) . 236

Taken together, these results demonstrate that MV-ATU2-SF-2P-dER induces a robust 237

Th1-driven T-cell immune response to SARS-CoV-2 S antigens at significantly higher levels than 238 MV-ATU3-SF-2P-dER. The S2 candidates elicited much lower cellular responses, as observed 239 previously with NAb levels, indicating that S2 alone is not sufficient to induce an efficient immune 240 response in these mice. We therefore excluded the S2 candidates from further analysis. 241 242

We monitored the persistence of anti-S antibodies in mice immunized twice with either MV-ATU2-244 SF-2P-dER or MV-ATU3-2F-2P-dER (Fig. 6a) . As usually observed for MV responses (Fig. 6b) , 245

S-specific IgG titers persisted and stabilized at high levels (10 5 -10 6 limiting dilution titers) for both 246 ATU2 and ATU3 candidates for up to three months after boosting (Fig 6c) . However, immunization 247 with the ATU2 construct resulted in significantly higher levels of S-specific IgG and NAb titers 248 (10 3 -10 4 limiting dilution titers) over the duration of the experiment (Fig. 6d) . 249

To determine whether these responses confer protection from SARS-CoV-2 infection, 250 immunized mice were challenged intranasally with 1.5 x 10 5 PFU of MACo3, a mouse-adapted 251 SARS-CoV-2 virus (Montagutelli et al, in prep). Three days after challenge, mice were sacrificed 252 and the presence of virus was examined in lung homogenates. SARS-CoV-2 RNA was measured 253 by RT-qPCR using RdRP gene-specific primers 36 (S. Table 2), and infectious virus levels were 254 titered on Vero E6 cells. SARS-CoV-2 viral RNA was detected in the lungs of all immunized mice 255 after challenge, with the ATU2 group showing an average 2log10 reduction and the ATU3 group 256 a 1log10 reduction compared to the empty MV control group (Fig. 6e) . However, no infectious virus 257 was detected in the lungs of the ATU2 group and all but one of the ATU3 group (Fig. 6f) . These 258 results demonstrate that, although viral replication occurred at low levels, infectivity of the 259 inoculated and progeny virus was efficiently neutralized. 260 261 Partial protection from intranasal challenge after a single immunization 262

We next determined whether a single immunization could protect IFNAR -/mice from challenge 263 with the MACo3 virus (Fig. 7a ). Immunized animals were examined for immune responses on 264 days 28 and 48 post-immunization, prior to challenge. All animals exhibited MV-and S-specific 265 antibodies (Fig. 7b , c). Th1-associated IgG responses to the S antigen as well as SARS-CoV-2 266

NAbs were present before challenge, although at lower levels than after two immunizations ( Fig.  267 7d, e). Mice were then challenged intranasally and lung samples collected 3 days after challenge. 268

Although no difference was observed in viral RNA levels between the test and control groups ( titer (10 6 TCID50) comparable to wild-type Schwarz MV strain and was genetically stable up to 10 282 passages while the previously reported rMV expressing the native S in the same promoter 283 showed impaired growth 37 . One explaination could be that the 2P mutation helps a stable S 284 protein expression therefore allowing rMV to grow better. Furthermore, MV-ATU2-SF-2P-dER 285 candidate elicited high levels of neutralizing antibodies to SARS-CoV-2 and strong Th1-oriented 286 T-cell reponses. Prime-boost immunization afforded protection from intranasal challenge with a 287 mouse-adapted SARS-CoV-2 virus. Moreover, NAb titers persisted months after the 288 immunization -such long-lasting immunity is a hallmark of replicating vector vaccines 38 . T-cell 289 responses, essential to controlling and reducing viral load and viral spread 39 , were induced within 290 seven days after a single immunization. Notably, dominance of Th1 responses suggests that 291 these vaccine candidates are less likely to induce immunopathology due to vaccine-induced 292 disease enhancement as previously reported for SARS-CoV-1 and MERS-CoV vaccine studies 293 40, 41, 42, 43, 44 . In addition, after a single immunization, our lead candidate MV-ATU2-SF-2P-dER 294 also provided sufficient immune protection according to WHO recommendations for a COVID-19 295 vaccine primary efficacy of at least 50% 45 . This suggests that our lead vaccine candidate can 296 protect against both SARS-CoV-2 infection and disease. 297

To explore the possibility of generating a broad-spectrum vaccine, we also tested a 298 vaccine candidate expressing only the S2 subunit, which is highly conserved among SARS-CoV-299 1 and SARS-CoV-2 viruses. The S2 subunit has been shown to harbor immunodominant and 300 neutralizing epitopes 16, 46, 47 . In this report, while S2 in the MV context induced high S-specific 301 antibody titers, these antibodies could not neutralize the SARS-CoV-2 virus. In terms of cellular 302 responses, S2 did not induce S-specific CD4 + , CD8 + or IL-5 + T-cell responses. These 303 observations suggest that the S2 subunit alone is insufficient for inducing immune protection. 304

Given the high titers of non-neutralizing antibodies, it would be interesting to characterize their 305 role in immune responses to SARS-CoV-2 infection and investigate whether they may contribute 306 to immunopathology. 307

Our results also yielded interesting differences in the immunogenicity of rMV vaccines 308 expressing the target antigen from ATU2 versus ATU3. S antigen is expressed at higher levels 309 from ATU2, and this correlated with higher humoral and cellular responses. Reducing the 310 immunization dose of the ATU2 candidate to 1x10 4 TCID50 still induced higher NAb titers than the 311 ATU3 vaccine at 1x10 5 TCID50 (S. Fig.8) . Additionally, T-cell responses to the MV vector was also 312 lower with ATU2 constructs. These observations suggest that higher antigen expression could be 313 First, as a replicating vector, MV-based vaccines can be administered at doses as low as 325 1x10 5 TCID50, compared to adenovirus-vectored vaccines that are generally administered at 10 10 -326 10 11 viral particles. Such high doses can run the risk of strong complement activation 49 , and the 327 preliminary report from phase I/II trials of AstraZeneca's ChAdOx1 indicated generally higher, 328 though acceptable, levels of adverse effects even with prophylactic paracetamol administration 329 50 . The lower doses relative to production titers render the vaccine more cost-effective for large-330 scale manufacturing as well. Additionally, replicating vectors are known to provide long-lasting 331 immunity 51, 52, 53 . Immune responses to our MV-ATU2-SF-2P-dER candidate lasted up to 4 months 332 after prime-boost immunization with no sign of decline, reflecting results seen for the MV-based 333 CHIKV vaccine 19 . By efficiently stimulating long-lasting memory B-and T-cells, MV induces both 334 humoral and cellular immune responses and provides life-long immunity. MV-CHIKV has an 335 efficacy rate of approximately 90% after one administration and 100% after two administrations. 336

Second, compared to inactivated and mRNA vaccines, formulation and distribution of MV-337 vectored vaccines is much simpler. The vector has been shown to naturally activate innate 338 immunity and possess self-adjuvanting properties 54 , and vaccination with live attenuated rMV 339 therefore does not require adjuvants. Common adjuvants such as alum have been characterized 340

to stimulate Th2-biased responses 35 , which could increase the possibility of immnunopathology. 341

Furthermore, rMV vaccines can be distributed with the existing cold-chain infrastructure, while 342 mRNA vaccines, which require ultra-cold temperatures will prove to be much more challenging. Interestingly, the MV vaccine is also known for its non-specific effects (NSEs) in reducing 349 children's mortality due to other viral infections 55, 56, 57 . This concept is being tested to see if there 

The SARS-CoV-2 spike (S) gene based on the sequence published by Zhou, Yang 4 was codon-377 optimized for expression in mammalian cells. Primers introducing restriction sites BsiWI and 378

BssHII to the S 5' and 3' ends, respectively, were used to amplify nucleotides 1-3799 to generate 379 full-length S (SF) with a deletion of its 11 C-terminal amino acids (SF-dER) (Fig. 1) for cloning into 380 pCDNA 5.1. To generate S2 constructs, primers were designed for inverted PCR with BsmBI 381 restriction sites and 4-nucleotide overlaps at the C-terminus of the native S signal peptide and S2 382 immediately adjacent to the furin cleavage site (Supplementary Table 2 ). The amplification 383 product, comprising the S2 region, the pCDNA backbone, and the S signal peptide, was digested 384

with BsmBI (NEB) and self-ligated to generate S2-dER. To maintain the conformation of S in the 385 prefusion state, two mutations were introduced at the hinge of HR1, K986P and V987P (2P 386 mutation) (Fig.1) . Primers introducing the mutations were designed with mutated overlapping 387 nucleotides and BsmBI sites (S. Table 2 ). The SF-dER and S2-dER constructs were amplified, 388 digested and self-ligated to create the prefusion-stabilized SF-2P-dER and S2-2P-dER 389

constructs. The S constructs in the pCDNA background were transfected into Vero cells using 390

FugeneHD. Transfected cells were observed at 24-and 48-hour post-transfection for fusogenic 391

All S genes were subsequently cloned into pTM-MVSchwarz encoding infectious MV cDNA 393 corresponding to the anti-genome of the MV Schwarz vaccine strain. All the inserted genes were 394 modified at the stop codon to ensure that the total number of nucleotides is a multiple of six 59 . 395

Rescue of recombinant MV viruses was performed using a helper-cell-based system as decribed 397 clarified by centrifugation, and titered as described above. 418

repeatedly infected for ten passages. Virus was collected by a freeze-thaw cycle after 1, 5 and 10 420 passages (P1, P5, P10) and used to infect Vero cells in 6 well-plates in duplicate. Cell lyzates 421 were then assessed for S mRNA and protein levels using RT-PCR, western blotting, and NGS 422 respectively. 423

To verify S expression from the rMV constructs, total RNA were extracted from infected Vero cells 425 using the RNeasy Mini Kit (Qiagen). The cDNA synthesis and PCR steps were performed using 426 the RNA LA PCR kit (Takara Bio) with primers (S. Table 2 ) targeting ATU2 and ATU3, according 427 to the manufacturer's instructions. RT-PCR products were verified by Sanger sequencing 428 (Eurofins Genomics) using the primers indicated in S. Table 2 . 

Extracted RNA was treated with Turbo DNase (Ambion) followed by purification using SPRI beads 445 (Agencourt RNA clean XP, Beckman Coulter). We used a ribosomal RNA (rRNA) depletion 446 approach based on RNAse H and targeting human rRNA. The RNA from the selective depletion 447 was used for cDNA synthesis using SuperScript IV (Invitrogen) and random primers, followed by 448 second-strand synthesis. Libraries were prepared using a Nextera XT kit and sequenced on an 449

Illumina NextSeq500 (2x150 cycles) at the Mutualized Platform for Microbiology hosted at Institut 450

Pasteur. Raw reads were trimmed using Trimmomatic v0.39 62 to remove adaptors and low-451 quality reads. We assembled reads using metaspades v3.14.0 63 with default parameters. 452

Scaffolds were queried against the NCBI non-redundant protein database (13) using DIAMOND 453 v2.0.4 (14) . No other viruses were detected. The recombinant MV genomes identified were 454 verified and corrected by iterative mapping using CLC Assembly Cell v5.1.0 (QIAGEN). Aligned 455 reads were manually inspected using Geneious prime v2020.1.2 (2020) 456 (https://www.geneious.com/), and consensus sequences were generated using a minimum of 5X 457 read-depth coverage to make a base call. Minor variants frequencies were estimated using Ivar 458 64 . 459

Vero cells were infected with various rMVs at an MOI of 0. and conducted in accordance with its guidelines. Groups of 6 to 8-week-old mice deficient for 482 type-I IFN receptor (IFNAR -/-) were intraperitoneally injected with 10 5 TCID50 rMV, namely SF-483 2P-dER or S2-2P-dER in ATU2 or ATU3, or the control empty MV Schwarz. To study humoral 484 responses, two immunizations were administered at a four-week interval. Sera were collected 485 before the first immunization (day -1) and then before (day 28) and after (day 42) after the second 486 immunization. All serum samples were heat-inactivated for 30 min at 56 °C. To assess protection, 487 mice that received either one or two immunizations were challenged with an intransal inoculation 488 Antibodies Online) were coated on NUNC MAXISORP 96-well immuno-plates (Thermo Fisher) at 498 1 µg/ml in 1x phosphate-buffered saline (PBS). Coated plates were incubated overnight at 4 °C, 499

washed 3 times with washing buffer (PBS, 0.05% Tween), and further blocked for 1 h at 37 °C 500 with blocking buffer (PBS, 0.05% Tween, 5% milk). Serum samples from immunized mice were 501 serially diluted in the binding buffer (PBS, 0.05% Tween, 2.5% milk) and incubated on plates for 502 1 h at 37 °C. After washing steps, an HRP-conjugated goat anti-mouse IgG (H+L) antibody 503 (Jackson ImmunoResearch, 115-035-146, 1:5000 dilution) was added for 1 h at 37 °C. Antibody 504 binding was detected by addition of the TMB substrate (Eurobio) and the reaction was stopped 505 with 100 µl of 30% H2SO4. The optical densities were recorded at 450 and 620 nm wavelengths 506 using the EnSpire 2300 Multilabel Plate Reader (Perkin Elmer). Endpoint titers for each individual 507 serum sample were calculated as the reciprocal of the last dilution giving twice the absorbance of 508 the negative control sera. Isotype determination of the antibody responses was performed using 509 HRP-conjugated isotype-specific (IgG1 or IgG2a) goat anti-mouse antibodies (AB97240 and 510 AB97245, Abcam, 1:5000). 511

Two-fold serial dilutions of heat-inactivated serum samples were incubated at 37 °C for 1 h with 513 50 PFU of SARS-CoV-2 virus in DMEM medium without FBS and added to a monolayer of Vero 514 E6 cells seeded in 24-well plates. Virus was allowed to adsorb for 2 h at 37 °C. The supernatant 515 was removed and the cells were overlaid with 1 ml of plaque assay overlay media (DMEM 516 supplemented with 5% FBS and 1.5% carboxymethylcellulose). The plates were incubated at 517 37 °C with 5% CO2 for 3 days. Viruses were inactivated and cells were fixed and stained with a 518 30% crystal violet solution containing 20% ethanol and 10% formaldehyde (all from Sigma). 519

Serum neutralization titer was counted on the dilution that reduced SARS-CoV-2 plaques by 50% 520 (PRNT50). 521

Splenocytes from immunized mice were isolated and red blood cells lysed using Hybri-Max Red 523 Mann-Whitney's U test was applied to compare differences between two groups. 568

The authors declare that the data supporting the findings of this study are available within this 570 article and its supplementary information files or available from the corresponding author upon 571 reasonable request. The source data files are provided with this paper. SD. Statistical significance was determined by a two-way ANOVA adjusted for multiple 901

comparisons. Asterisks (*) indicate significant mean differences (** p < 0.01, and **** p < 0.001) 902

as determined by the Mann-Whitney U-test. 903 CoV-2 S peptide pools specific to CD8 + or CD4 + T cells. d) Ratio of IFNγ-secreting cells stimulated 911 by CD4 + or CD8 + peptides to those stimulated by MV Schwarz. Each data point represents an 912 individual mouse. Asterisks (*) indicate significant mean differences (* p < 0.05; ** p < 0.01, and 913 **** p < 0.001) as determined by the Mann-Whitney U-test. 914 splenocytes were stimulated with S-specific peptide pools. S-specific a) CD8 + and b) CD4 + T-cells 920

were stained for intracellular IFNγ, TNFα and IL-5. Asterisks (*) indicate significant mean 921 differences (* p < 0.05; ** p < 0.01, and **** p < 0.001) as determined by the Mann-Whitney U-test. 922 as 50% plaque reduction neutralization test (PRNT50) titers. e) SARS-CoV-2 viral RNA copies 933 detected by RT-qPCR in homogenized lungs of challenged animals, calculated as copies/lung. f) 934

Titer of infectious viral particles recovered from the homogenized lung of the immunized animals 935 expressed as PFU/lung. Data are represented as geometric means with line and error bars 936

indicating geometric SD. Statistical significance was determined by a two-way ANOVA adjusted 937 for multiple comparisons. Asterisks (*) indicate significant mean differences (* p < 0.05; ** p < 0.01, 938

and **** p < 0.001). 939

The GDP@Risk over five years from COVID-19 could range from $3.3 591 trillion to $82 trillion, says the Centre for

China coronavirus: Six questions scientists are 596 asking

Rapid COVID-19 vaccine development

A pneumonia outbreak associated with a new coronavirus of 602 probable bat origin

A new coronavirus associated with human respiratory disease in

Proteolytic Cleavage of the SARS-CoV-2

Spike Protein and the Role of the Novel S1/S2 Site. Ssrn

SARS-CoV-2 Cell Entry Depends on ACE2 and 611 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The spike protein of SARS

CoV--a target for vaccine and therapeutic development

Protection from SARS coronavirus conferred by live 619 measles vaccine expressing the spike glycoprotein

Safety, tolerability, and immunogenicity of a recombinant 633 adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-634 label, non-randomised, first-in-human trial

Severe acute respiratory syndrome coronavirus

CoV) infection inhibition using spike protein heptad repeat-derived peptides

Proceedings of the National Academy of Sciences of the United States of 640 America

Amino acids 1055 to 1192 in the S2 region of severe acute 643 respiratory syndrome coronavirus S protein induce neutralizing antibodies: 644 implications for the development of vaccines and antiviral agents

Monoclonal antibodies targeting the HR2 domain and the 648 region immediately upstream of the HR2 of the S protein neutralize in vitro 649 infection of severe acute respiratory syndrome coronavirus

Identification of an antigenic determinant on the S2 domain 653 of the severe acute respiratory syndrome coronavirus spike glycoprotein 654 capable of inducing neutralizing antibodies

B-cell responses in patients who have recovered from severe 658 acute respiratory syndrome target a dominant site in the S2 domain of the 659 surface spike glycoprotein

Measles-derived vaccines to prevent 662 emerging viral diseases

Immunogenicity, safety, and tolerability of a recombinant 665 measles-virus-based chikungunya vaccine: a randomised, double-blind, 666 placebo-controlled, active-comparator, first-in-man trial

Immunogenicity, safety, and tolerability of the measles-670 vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, 671 placebo-controlled and active-controlled phase 2 trial

Vaccines inducing immunity to Lassa virus glycoprotein and 675 nucleoprotein protect macaques after a single shot

A 679 Measles Virus-Based Vaccine Candidate Mediates Protection against Zika 680 Virus in an Allogeneic Mouse Pregnancy Model

A Highly Immunogenic and Protective Middle East 684 Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant 685

Measles Virus Vaccine Platform

Genomic characterization of the 2019 novel human-689 pathogenic coronavirus isolated from a patient with atypical pneumonia after 690 visiting Wuhan. Emerging microbes & infections 9

Stabilized coronavirus spikes are resistant to 693 conformational changes induced by receptor recognition or proteolysis

Immunogenicity and structures of a rationally designed 697 prefusion MERS-CoV spike antigen

Cryo-EM structure of the 2019-nCoV spike in the prefusion 701 conformation

The contribution of the 704 cytoplasmic retrieval signal of severe acute respiratory syndrome 705 coronavirus to intracellular accumulation of S proteins and incorporation of 706 S protein into virus-like particles

The cytoplasmic tail of the severe acute 710 respiratory syndrome coronavirus spike protein contains a novel 711 endoplasmic reticulum retrieval signal that binds COPI and promotes 712 interaction with membrane protein

Incorporation of spike and membrane glycoproteins 716 into coronavirus virions

A novel sorting signal for intracellular 719 localization is present in the S protein of a porcine coronavirus but absent 720 from severe acute respiratory syndrome-associated coronavirus

A molecularly cloned Schwarz strain of measles virus 724 vaccine induces strong immune responses in macaques and transgenic mice

Dynamics of viral RNA synthesis during 728 measles virus infection

731 hCD46 receptor is not required for measles vaccine Schwarz strain 732 replication in vivo: Type-I IFN is the species barrier in mice

Lymphokine control of in vivo immunoglobulin 736 isotype selection

Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-2

Protocol: Real-time RT-PCR assays for the detection 740 of SARS-CoV-2

A highly immunogenic and effective measles virus-based

Th1-biased COVID-19 vaccine

Duration of humoral immunity to 747 common viral and vaccine antigens

Antigen-Specific Adaptive Immunity to 750 SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease 751 Severity

Immunogenicity and protective efficacy in mice and 754 hamsters of a beta-propiolactone inactivated whole virus SARS-CoV 755 vaccine

Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus 759

Macaques Immunized with an Inactivated SARS-CoV Vaccine

Immunogenicity and protective efficacy in monkeys of purified 763 inactivated Vero-cell SARS vaccine

A novel human mAb (MERS-GD27) provides prophylactic and 766 postexposure efficacy in MERS-CoV susceptible mice

Identification of an ideal adjuvant for receptor-binding 770 domain-based subunit vaccines against Middle East respiratory syndrome 771 coronavirus

VACCINESFORWHO EUL v24092020

Devices Assessment Team (VAX) PUP, Regulation and Prequalification 776

Access to Medicineand Health Products(MHP)

Identification of immunodominant sites on the spike protein of 780 severe acute respiratory syndrome (SARS) coronavirus: implication for 781 developing SARS diagnostics and vaccines

Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia 786

Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

Print RDB. Draft landscape of COVID-19 candidate vaccines.). World 790 Health Organization

Adenoviral vector immunity: its 793 implications and circumvention strategies

Safety and immunogenicity of the ChAdOx1 nCoV-19 797 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-798 blind, randomised controlled trial

Attenuated measles virus as a vaccine vector

Long-term immunity against yellow fever in children 805 vaccinated during infancy: a longitudinal cohort study

Immunogenicity of second dose measles-mumps-rubella 809 (MMR) vaccine and implications for serosurveillance

Komarova 813 AV. Nonencapsidated 5' Copy-Back Defective Interfering Genomes 814 Produced by Recombinant Measles Viruses Are Recognized by RIG-I and 815 LGP2 but Not MDA5

The non-specific effects of vaccines and other childhood 818 interventions: the contribution of INDEPTH Health and Demographic 819 Surveillance Systems

Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on 823 Overall Survival: A Review

Non-specific effects of standard measles vaccine at 4.5 and 9 826 months of age on childhood mortality: randomised controlled trial

Occurrence and transmission potential of 830 asymptomatic and presymptomatic SARS-CoV-2 infections: A living 831 systematic review and meta-analysis

The rule of six, a basic feature for efficient replication of 834 Sendai virus defective interfering RNA

Modulating the function of the measles 838 virus RNA-dependent RNA polymerase by insertion of green fluorescent 839 protein into the open reading frame

Beitrag zur kollektiven Behandlung pharmakologischer

Trimmomatic: a flexible trimmer for 847 Illumina sequence data

metaSPAdes: a new 851 versatile metagenomic assembler

An amplicon-based sequencing framework for 854 accurately measuring intrahost virus diversity using PrimalSeq and iVar

S2-dER from either ATU2 or ATU3, with or without the 2P mutation. d) Immunofluorescence 885 staining of Vero cells infected with the indicated rMVs 24 h after infection. Permeabilized or non-886 permeabilized cells were stained for S (red

significance for antibody responses (top panels) was determined by two-way ANOVA adjusted 952for multiple comparisons. The rest of the data (bottom panels) was analyzed by the Mann-Whitney 953 U-test. Asterisks (*) indicate significant mean differences (* p < 0.05; ** p < 0.01, and **** 954 p < 0.001). 955